FDA approves new influenza vaccine production facility
This article was originally published in The Gold Sheet
Executive Summary
On May 6 FDA announced approval of a new influenza vaccine manufacturing facility in Swiftwater, Pa., for the production of the influenza H1N1 (swine flu) virus. The facility is owned and operated by Sanofi Pasteur, which is one of the nation's largest seasonal flu vaccine producers as well as one of the world's earliest developers of vaccines. Sanofi will use the new facility to manufacture Fluzone, an egg-based influenza vaccine. The company finished constructing the $150 million, 140,000 square foot plant in July 2007 and the facility is now operating. On another front, the vaccine giant just announced that it just started construction of a new vaccine production center in Neuville-sur-Saone, in southeastern France, for the tropical dengue virus
|
On May 6 FDA announced approval of a new influenza vaccine manufacturing facility in Swiftwater, Pa., for the production of the influenza H1N1 (swine flu) virus. The facility is owned and operated by Sanofi Pasteur, which is one of the nation's largest seasonal flu vaccine producers as well as one of the world's earliest developers of vaccines. Sanofi will use the new facility to manufacture Fluzone, an egg-based influenza vaccine. The company finished constructing the $150 million, 140,000 square foot plant in July 2007 and the facility is now operating. On another front, the vaccine giant just announced that it just started construction of a new vaccine production center in Neuville-sur-Saone, in southeastern France, for the tropical dengue virus. |